Advertisement
TC BioPharm Inks LOI To Acquire Privately-held CAR-T Therapy Innovator
(RTTNews) - Biotechnology company TC BioPharm (Holdings) plc (TCBP) announced Monday the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors.
This agreement is the second such agreement in as many months that shows TC BioPharm's commitment to its M&A strategy aimed at expanding its therapeutic platform.
CAR T-cell therapy modifies a patient's own immune cells to provide a heightened ability to identify and eliminate cancer cells.
The target acquisition has developed a number of proprietary approaches to re-engineer CARs to better target solid tumors. The Company has generated pre-clinical proof of concept data that demonstrates the therapeutic potential of its lead CAR-T candidate for a range of solid tumors including colorectal, pancreatic, mesothelioma, ovarian and breast cancer
In addition, the target acquisition is also developing a novel, allogeneic CAR-T for the treatment of autoimmune diseases.
TC BioPharm Unveils Corporate Restructuring Plan; To Cut Up To 30% Of Workforce
Canadian Dollar Eases Against Most Majors
Swiss Market Ends Sharply Lower
European Stocks Close Weak As Trade War Fears Hurt Sentiment
Canadian Market Remains Weak On Tariff Concerns
Bay Street Likely To Open Lower
Pound Falls As U.K. Economy Contracts For Second Straight Month
